The bill amends the Public Health Service Act to allow individuals to sue vaccine manufacturers and administrators in state or federal court for vaccine‑related injury or death regardless of whether they have filed (or have pending) a petition in the National Vaccine Injury Compensation Program (NVICP). It creates a mutual bar: a civil judgment or settlement bars NVICP compensation for the same injury, and an NVICP award bars later civil suits; pending claims in one forum are to be dismissed when relief is obtained in the other.
The measure also repeals statutory provisions that govern the NVICP election, standards of responsibility, and trial procedures, makes conforming edits to fee and payment rules, adjusts limitations language, and removes COVID‑19 vaccines from the statutory definition of “covered countermeasure” (the scope of PREP Act protections). Those changes reopen tort liability for vaccines and remove a pandemic‑era carveout for COVID‑19 vaccines — a substantive legal shift with direct implications for manufacturers, providers, insurers, and public health response planning.
At a Glance
What It Does
The bill inserts a new statutory right to bring civil actions against vaccine administrators and manufacturers for vaccine‑related injuries or deaths, and establishes that a civil judgment or settlement precludes NVICP compensation for that same injury (and vice versa). It repeals sections of the NVICP that previously governed election and trial procedures and modifies related fee, payment, and limitations provisions. Separately, it amends the PREP Act definition of 'covered countermeasure' to exclude COVID‑19 vaccines.
Who It Affects
Vaccine manufacturers and distributors, clinicians and other vaccine administrators, claimants who have used or would use the NVICP, the Department of Health and Human Services (which administers NVICP), plaintiffs’ lawyers and state/federal courts handling product‑liability suits, and insurers that underwrite manufacturers and providers.
Why It Matters
The bill shifts liability exposure from a largely federal compensation program into the ordinary civil‑justice system and strips pandemic immunity for COVID‑19 vaccines — changing legal risk calculations for manufacturers and potentially altering vaccine availability, pricing, and the design of emergency‑response incentives.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill rewrites how individuals who allege vaccine‑related injury seek redress. It adds a provision to the NVICP statute giving claimants an explicit right to file a civil lawsuit against a vaccine administrator or manufacturer in state or federal court irrespective of NVICP filing status.
That new right is not unrestricted: the bill pairs it with a mutual‑exclusivity rule that prevents double recovery — if a claimant obtains a civil judgment or settlement, they cannot obtain NVICP compensation for the same injury, and if the NVICP awards compensation, the claimant cannot proceed with a civil suit. The text also requires dismissal of pending petitions or civil actions when the claimant recovers in the other forum.
To clear the statutory path for civil litigation, the bill repeals three NVICP provisions: the election provision that formerly structured a claimant’s choice between the Program and civil court, statutory 'standards of responsibility' unique to NVICP adjudications, and trial provisions that governed how claims in the Program were litigated. With these repeals, tort claims will proceed under ordinary state and federal product‑liability rules rather than under the special NVICP regime.The bill makes several technical but consequential conforming edits.
It removes or reshuffles NVICP language on attorneys’ fees and payment mechanics, alters limitations‑of‑action language so that state statutes of limitation interact differently with the federal program, and strikes a six‑month timing phrase from an existing subsection (modifying a specific timing constraint embedded in current NVICP text). These edits change procedural hooks that previously governed when and how claimants could sue or obtain Program relief.Separately, the bill takes COVID‑19 vaccines out of the PREP Act’s definition of a 'covered countermeasure.' That is a targeted carveout: even when the Secretary declares a public‑health emergency under section 319, COVID‑19 vaccines would not receive the immunity and exclusivity that the PREP Act gives to designated countermeasures during emergencies.
Together, these changes reopen civil courts to vaccine‑injury litigation and remove pandemic‑era liability protections for COVID‑19 vaccines, with downstream consequences for litigation risk, commercial insurance, and emergency‑response incentives.
The Five Things You Need to Know
The bill authorizes claimants to bring civil suits against vaccine manufacturers and administrators for vaccine‑related injury or death 'beginning on the date of enactment' regardless of NVICP filing status.
It creates a mutual bar: a civil judgment or settlement precludes NVICP compensation for the same injury, and an NVICP award precludes bringing a civil action; pending claims in the other forum must be dismissed.
The bill repeals three NVICP provisions: section 2121(a) (the election mechanism), section 2122 (standards of responsibility), and section 2123 (trial rules).
It amends the PREP Act definition of 'covered countermeasure' to expressly exclude any vaccine used to mitigate, prevent, or treat COVID‑19, removing PREP immunity for those vaccines.
The text makes multiple conforming edits — removing a six‑month timing phrase in section 2111(c)(1)(B)(i)(III), changing attorneys’‑fee and payment provisions, and adjusting limitations‑of‑action language in section 2116(b).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Creates a statutory right to sue and sets a mutual recovery bar
This provision inserts a new paragraph that authorizes civil actions against vaccine administrators and manufacturers irrespective of NVICP petition status, while adding a reciprocal prohibition that prevents double recovery: a civil judgment or settlement bars later NVICP petitions and NVICP compensation bars later civil suits. Practically, claimants must realize that recovery in one forum forecloses relief in the other and that pending matters will be dismissed once one forum provides relief, which changes strategic choices for claimants and counsel.
Narrows the NVICP exception to state limitations rules
Section 2116(b) is edited to incorporate the new mutual‑exclusivity limitation by adding cross‑reference language: the previously distinct phrasing about actions 'notwithstanding section 2111(b)(2)' is retained but now explicitly yields where section 2111(a)(4)(A) prohibits suit. That change tightens the interaction between state statutes of limitation and the Program’s mechanisms, potentially affecting when claimants must sue in court versus filing with NVICP.
Removes NVICP election, Program standards, and trial provisions
The bill repeals the statutory election rule that once allowed narrow civil‑action elections in lieu of Program adjudication, as well as the special standards of responsibility and the Program’s trial procedure provisions. Removing these clauses transfers contested‑fact determinations and liability standards back into ordinary court processes and state tort law rather than the NVICP’s specialized framework.
Edits to fees, payments, state‑action rules, and Program termination language
To align the statute with the larger rework, the bill deletes specific paragraphs governing attorneys’ fees and restructures payment‑of‑compensation language, excises an authorization tied to an 'election' mechanism, and changes termination and state‑action cross‑references. Those edits are procedural but meaningful: they affect how counsel are compensated, how and whether NVICP funds are paid relative to civil judgments, and the downstream administrative mechanics for HHS and the Court of Federal Claims.
Excludes COVID‑19 vaccines from 'covered countermeasure' status
The bill rewrites the PREP Act’s 'covered countermeasure' definition to state explicitly that it 'does not include any vaccine used to mitigate, prevent, or treat COVID‑19.' That targeted exclusion means COVID‑19 vaccines would not enjoy PREP Act immunity from suit during declared public‑health emergencies, a material change from existing law where many COVID‑era countermeasures were treated as covered.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals alleging vaccine injury — they regain direct access to state and federal courts and may pursue full tort remedies (including punitive or non‑economic damages available under state law) that the NVICP’s statutory regime previously constrained.
- Plaintiffs’ attorneys and tort‑litigation firms — the bill expands the pool of meritorious cases that can be litigated in tort, creating new demand for counsel and discovery‑driven litigation.
- State courts and trial judges — they will preside over an increased volume of complex product‑liability cases previously funneled into the federal Program, which can raise local legal‑service activity and precedent development.
Who Bears the Cost
- Vaccine manufacturers and developers — they face renewed exposure to product‑liability suits and settlements, which could increase liability costs, insurance premiums, and risk assessments for vaccine R&D and manufacturing.
- Vaccination providers and administrators (clinics, pharmacies, hospitals) — the bill names 'vaccine administrators' as potential defendants, expanding their litigation risk and likely raising professional‑liability insurance costs or operational caution around vaccine delivery.
- Federal agencies and the NVICP — HHS will need to handle dismissed or converted claims, adjust payment and compensation processes, and manage administrative transitions, imposing implementation burdens without appropriation language.
- Public‑health programs and taxpayers — potential increases in vaccine prices, reduced manufacturer willingness to supply certain markets, or slowed emergency deployment could have fiscal and programmatic consequences borne by governments and health systems.
Key Issues
The Core Tension
The central dilemma is straightforward: restore full access to civil justice for people who allege vaccine harm, or preserve a predictable, federally managed liability regime that keeps vaccines widely available and affordable during routine and emergency responses — the bill chooses the former at the risk of undermining the latter, forcing a trade‑off between individual remedies and public‑health incentives.
The bill resolves one policy goal — expanding access to civil courts — by creating hard procedural trade‑offs that raise implementation and policy questions. First, the mutual‑exclusivity mechanism reduces double recovery risk but invites tactical filings, forum shopping, and complex timing disputes: claimants and defendants will litigate which forum first obtained effective relief and whether dismissals were appropriate.
The statute’s deletion of specialized NVICP standards and trial rules means courts will apply ordinary tort doctrines to injuries that the Program once handled under a unique evidentiary and causation framework, producing unpredictability in outcomes and likely higher discovery costs.
Second, removing PREP Act coverage for COVID‑19 vaccines separates pandemic liability policy from the NVICP changes and imposes a discontinuity in emergency legal protections. That carveout may discourage manufacturer participation in future COVID‑related vaccine programs or shift negotiations over indemnities and procurement contracts to private arrangements.
The bill is short on implementation detail: it does not address allocation of FDA‑issued emergency‑use or full approvals, retroactivity for pending NVICP or court cases, or whether HHS will receive funds or staffing to process dismissed petitions. Those gaps create litigation and administrative risk in the transition to a post‑carveout regime.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.